Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Raj Bandaru"'
Autor:
Daniel Basoff, Anju Parthan, Raj Bandaru, Anusorn Thanataveerat, Matthew Kent, Michael Hehir, Ali A. Habib
Publikováno v:
Sunday, April 23.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2b237f2a45080663012f96456ef45f2
https://doi.org/10.1212/wnl.0000000000202377
https://doi.org/10.1212/wnl.0000000000202377
Autor:
Lee M. Greenberger, Ivan D. Horak, Robert L. Vessella, Hong Zhao, Raj Bandaru, Puja Sapra, Jenny Pak, Ying Gao, Patricia Kraft, Victoria Shi, Steven Kim, Zhengxing Qu, Mary Mileski, Maoliang Wang, Melissa Dumble, Stephen Castaneda, Yixian Zhang
PDF file - 304K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122f845b833c3fd22bfeb72faad78f38
https://doi.org/10.1158/1535-7163.22497225.v1
https://doi.org/10.1158/1535-7163.22497225.v1
Autor:
Mark W. Kieran, Tobey J. MacDonald, Alain C. Mita, Anne L. Thomas, Jordi Rodon, Hussein A. Tawbi, Michela Casanova, Darren R. Hargrave, David M. Ashley, François Doz, Birgit Geoerger, Yuichi Ando, Raj Bandaru, Asifa S. Haider, Thad Sharp, Keith L. Ligon, Yoon-Jae Cho, Kristine L. Rose, Dereck D. Amakye, Douglas M. Robinson, Yaping Shou
Supplementary Methods and Supplementary Table 1. The supplementary data file contains the supplemental methods section describing the source of the patient samples used in the initial validation of the five-gene signature assay and supplementary tabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe14340d80cc4ea2c2f77c828f7abe9
https://doi.org/10.1158/1078-0432.22446726.v1
https://doi.org/10.1158/1078-0432.22446726.v1
Autor:
Humphrey Gardner, J. Carl Barrett, Wolfgang Hackl, Weihua Liu, Raj Bandaru, Marianne Ewertz, Ann Knoop, Anne-Vibeke Laenkholm, Jeanette Dupont Jensen
Purpose:PIK3CA mutations are frequent in breast cancer and activate the PI3K/Akt pathway. Unexpectedly, PIK3CA mutation appears in general to be associated with better outcome. In a cohort of patients where both primary and metastatic lesions were av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f80ea41f2d317aced3d9862a6070c5
https://doi.org/10.1158/1078-0432.c.6518097.v1
https://doi.org/10.1158/1078-0432.c.6518097.v1
Autor:
Humphrey Gardner, J. Carl Barrett, Wolfgang Hackl, Weihua Liu, Raj Bandaru, Marianne Ewertz, Ann Knoop, Anne-Vibeke Laenkholm, Jeanette Dupont Jensen
Supplementary Tables S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::076e981c17945629ee4093db1222227f
https://doi.org/10.1158/1078-0432.22440828.v1
https://doi.org/10.1158/1078-0432.22440828.v1
Autor:
Mark W. Kieran, Tobey J. MacDonald, Alain C. Mita, Anne L. Thomas, Jordi Rodon, Hussein A. Tawbi, Michela Casanova, Darren R. Hargrave, David M. Ashley, François Doz, Birgit Geoerger, Yuichi Ando, Raj Bandaru, Asifa S. Haider, Thad Sharp, Keith L. Ligon, Yoon-Jae Cho, Kristine L. Rose, Dereck D. Amakye, Douglas M. Robinson, Yaping Shou
Purpose: Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway–activated disease, have been reported. We identified and clinically validated a five-gene Hh signature assay that can be used to preselect patients with Hh pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::276e8fec02b2f594765c7d221e11b764
https://doi.org/10.1158/1078-0432.c.6520848.v1
https://doi.org/10.1158/1078-0432.c.6520848.v1
Autor:
Daniel G. Anderson, Raj Bandaru, Chenyue Lu, Xin Chen, Yixian Zhang, Taylor Gill, Linda T. Nieman, James E. Bradner, Matthew A. Lawlor, Christopher J. Ott, Junyan Tao, David T. Ting, Haichuan Wang
Publikováno v:
Oncogene. 40(47)
MYC is a prolific proto-oncogene driving the malignant behaviors of numerous common cancers, yet potent and selective cell-permeable inhibitors of MYC remain elusive. In order to ultimately realize the goal of therapeutic MYC inhibition in cancer, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fdee32dcf5a4bcef3373727dee50c7
https://pubmed.ncbi.nlm.nih.gov/34650218
https://pubmed.ncbi.nlm.nih.gov/34650218
Autor:
Anne L. Thomas, Alain C. Mita, Yuichi Ando, Mark W. Kieran, Yoon Jae Cho, Hussein Tawbi, David M. Ashley, Jordi Rodon, Yaping Shou, François Doz, Darren Hargrave, Douglas Robinson, Dereck Amakye, Birgit Geoerger, Keith L. Ligon, Tobey J. MacDonald, Michela Casanova, Raj Bandaru, Thad Sharp, Kristine Rose, Asifa Haider
Publikováno v:
Clinical Cancer Research. 21:585-593
Purpose: Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway–activated disease, have been reported. We identified and clinically validated a five-gene Hh signature assay that can be used to preselect patients with Hh pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90455d88abad5b18f97607020ebc6a45
https://doi.org/10.1158/1078-0432.ccr-13-1711
https://doi.org/10.1158/1078-0432.ccr-13-1711
Autor:
Patricia Kraft, Raj Bandaru, Victoria Shi, B. Liao, Ivan D. Horak, Zhengxing Qu, Yixian Zhang, Steven Kim, Lee M. Greenberger, Yaming Wu
Publikováno v:
Gene Therapy
Usually, small interfering RNAs and most antisense molecules need mechanical or chemical delivery methods to down-modulate the targeted mRNA. However, these delivery approaches complicate the interpretations of biological consequences. We show that l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de59eeb8144fe3aabd6d1a458f7e522
http://europepmc.org/articles/PMC3154478
http://europepmc.org/articles/PMC3154478
Autor:
Li Lin, John A. Olson, Sherri R. Davies, Kelly K. Hunt, Weihua Liu, Vladimir Semiglazov, Matthew J. Ellis, Katherine DeSchryver, Robert J. Crowder, Raj Bandaru, Jutta Steinseifer, Yu Tao, Mark A. Watson, Dean B. Evans, José Baselga, Jeremy Hoog, Humphrey Gardner, Jacqueline E. Snider
Publikováno v:
Breast Cancer Research and Treatment. 119:379-390
Mutations in the alpha catalytic subunit of phosphoinositol-3-kinase (PIK3CA) occur in approximately 30% of ER positive breast cancers. We therefore sought to determine the impact of PIK3CA mutation on response to neoadjuvant endocrine therapy. Exons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e95b0a72bec63f79917fb625a28a51
https://doi.org/10.1007/s10549-009-0575-y
https://doi.org/10.1007/s10549-009-0575-y